Effect of obesity on recombinant follicle-stimulating hormone absorption: subcutaneous versus intramuscular administration
Authors:
- Michael P SteinkampfMSMichael P Steinkampf
- Karen R HammondKHKaren R Hammond
- John E NicholsJNJohn E Nichols
- Scott H SlaydenSSScott H Slayden
- 1 July 2003
- journal article
- clinical trial
- Published by Elsevier in Fertility and Sterility
- Vol. 80 (1) , 99-102
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Differences in serum follicle-stimulating hormone uptake after intramuscular and subcutaneous human menopausal gonadotropin injectionFertility and Sterility, 1994
- Clinical pharmacology of recombinant human follicle-stimulating hormone. II. Single doses and steady state pharmacokineticsFertility and Sterility, 1994
- The relationship between body composition and plasma concentrations of exogenously administered urinary follicle stimulating hormoneHuman Reproduction, 1993
- Body weight, body mass index, and age: predictors of menotropin dose and cycle outcome in polycystic ovarian syndrome?Fertility and Sterility, 1992
- Failure of body mass index or body weight to influence markedly the response to ovarian hyperstimulation in normal cycling womenFertility and Sterility, 1990
- Positive correlation between body weight, length of human menopausal gonadotropin stimulation, and oocyte fertilization rateFertility and Sterility, 1986
- Intramuscular or Intralipomatous Injections?New England Journal of Medicine, 1982